Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 17/10/2019
SIETES contiene 92825 citas

<< anterior 21 a 40 de 271 siguiente >>
Presentar resultados
Seleccionar todas
22. Cita con resumen
Sasich LD, Abi-Jaoude E. Sharing of clinical trial data. FDA drug approval packages are already freely available. BMJ 2013;347:19. [Ref.ID 96167]
23.Tiene citas relacionadas Cita con resumen
Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 2013;346:23-6. [Ref.ID 95962]
24.Tiene citas relacionadas
Schroll JB, Bero L, Gotzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 2013;346:12. [Ref.ID 95960]
25.Tiene citas relacionadas Cita con resumen
Loder E, Godlee F, Barbour V, Winker M. Restoring the integrity of the clinical trial evidence base. BMJ 2013;346:7. [Ref.ID 95959]
28.Tiene citas relacionadas
Barr IG, Hurt AC. Double dose oseltamivir for severe influenza - does it help?. BMJ 2013;346:10. [Ref.ID 95911]
29. Cita con resumen
Kmietowicz Z. MP says choice of oseltamivir in flu pandemic was worrying. BMJ 2013;346:5. [Ref.ID 95670]
30. Cita con resumen
Chavant F, Ingrand I, Jonville-Bera AP, Plazanet C, Gras-Champel V, Lagarce L, Zenut M, Disson-Dautriche A, Logerot S, Auffret M, Coubret-Dumas A, Bruel ML, Boyer M, Bos-Thompson MA, Veyrac G, Carlier P, Beyens MN, Lates S, Damase-Michel C, Castot A, Kreft-Jaïs C, Pérault-Pochat MC. The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza. Drug Saf 2013;36:455-65. [Ref.ID 95665]
31. Cita con resumen
Doshi P. Influenza vaccines: time for a rethink. JAMA Intern Med 2013;173:1014-6. [Ref.ID 95613]
32. Cita con resumen
Greene SK, Li L, Shay DK, Fry AM, Lee GM, Jacobsen SJ, Baxter R, Irving SA, Jackson ML, Naleway AL, Nordin JD, Narwaney KJ, Lieu TA. Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010. Pharmacoepidemiol Drug Saf 2013;22:335-44. [Ref.ID 95208]
33. Cita con resumen
Rubinstein F, Micone P, Bonotti A, Wainer V, Schwarcz A, Augustovski F, Riviere AP, Karolinski A, on behalf of "EVA" Study Research Group (Estsudio "Embarazo y Vacuna Antigripal"). Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ 2013;346:14. [Ref.ID 94977]
34. Cita con resumen
Krumholz HM, Jackevicius CA, Ross JS. Tamiflu: 14 flu seasons and still questions. BMJ 2013;346:9. [Ref.ID 94927]
36. Cita con resumen
Háberg SE, Trogstad L, Gunnes N, Wilcox AJ, Gjessing HK, Samuelsen SO, Skrondal A, Cappelen I, Engeland A, Aavitsland P, Madsen S, Buajordet I, Furu K, Nafstad P, Vollset SE, Feiring B, Nokleby H, Magnus P, Stottenberg C. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med 2013;368:333-40. [Ref.ID 94807]
38. Cita con resumen
McKittrick N, Frank I, Jacobson JM, White CJ, Kim D, Kappes R, Digiorgio C, Kenney T, Boyer J, Tebas P, and for the Center for AIDS Research. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med 2013;158:19-26. [Ref.ID 94681]
39. Cita con resumen
Anónimo. FDA approves next-generation flu vaccine. DIA Daily 2013:17 de enero. [Ref.ID 94631]
40.Tiene citas relacionadas Cita con resumen
Rawlins M. We will look again at NICE appraisal of Tamiflu. BMJ 2012;345:28. [Ref.ID 94248]
Seleccionar todas
<< anterior 21 a 40 de 271 siguiente >>